Medications 55-69 years old, the decision undergo periodic PSA-based screening for prostate cancer should be individualized and include a discussion of the potential benefits and harms screening
Screening offers a potential benefit of reducing the chance of death from prostate cancer in some men.
Harms of screening include additional testing and possible prostate biopsy as a result of false positives, over diagnosis and overtreatment as well as treatment associated complications including incontinence and erectile dysfunction
Factors to be considered include family history, rates, ethnicity, medical comorbidities, as well as patient’s personal values and believes about diagnoses and intervention
In patients older than 7 years old, the task force recommended against PSAP screening